QIAGEN Earnings Call: Growth Pillars Offset Near-Term Drag

Qiagen ((QGEN)) has held its Q4 earnings call. Read on for the main highlights of the call.

QIAGEN closed 2025 on a confident note, with management striking an upbeat tone despite acknowledging several short-term headwinds. The company beat its Q4 and full-year guidance on both sales and earnings, expanded margins and generated strong free cash flow, all while investing in core growth platforms and strategic acquisitions. At the same time, executives were candid about pressure in PCR and NGS consumables, weaker demand in the U.S. and China, and tariff and currency drag. The underlying message to investors: 2025 validated QIAGEN’s strategy and balance sheet strength, but 2026 will be a transition year with a slower first half and acceleration expected as new products and growth pillars scale.

Q4 Results Beat Expectations

QIAGEN’s fourth quarter of 2025 came in ahead of its own outlook, underscoring resilient demand in key franchises. Net sales reached $540 million, up 1% at constant exchange rates (CER), beating guidance that had assumed flat growth. Adjusted diluted EPS came in at $0.62 at CER versus an outlook of about $0.60. This performance is notable given a cautious spending environment in life sciences and lingering macro uncertainty, and it provides a firmer base for the company’s 2026 guidance.

Full-Year 2025 Performance at the High End of Guidance

For the full year 2025, QIAGEN delivered net sales of $2.09 billion, representing 5% growth at CER and landing at the high end of its 4%–5% outlook range. Adjusted diluted EPS was $2.40 at CER (reported $2.38), exceeding guidance despite two upward revisions during the year. This suggests the company not only executed consistently but also maintained earnings discipline while investing in future growth. For investors, the combination of top-line and bottom-line outperformance strengthens confidence in management’s ability to navigate a mixed demand backdrop.

Growth Pillars Gain Momentum

The company’s designated growth pillars—Sample Technologies, QuantiFERON, QIAstat, QIAcuity and QIAGEN Digital Insights (QDI)—were a clear bright spot. Combined, these businesses generated $1.49 billion in 2025, growing 8% at CER year-over-year. Management reiterated its target of at least $2 billion in annual sales from these pillars by 2028. The growing weight of these higher-growth, often higher-margin franchises in the overall portfolio is central to QIAGEN’s long-term growth and profitability narrative.

Sample Technologies: Core Engine with Strategic Expansion

Sample Technologies, a core foundation of QIAGEN’s business, posted mid-single-digit growth in Q4 2025 (+5% CER) and 2% CER for the full year. The installed base has grown to roughly 31,400 placements, giving the company a wide and sticky footprint in labs. Within this segment, liquid biopsy sample preparation stood out with growth above 30%, reflecting increasing adoption of noninvasive testing. The acquisition of Parse Biosciences adds single-cell capabilities to this platform, broadening the technology offering and positioning QIAGEN to benefit from the expanding single-cell research market—even though the deal will carry some near-term dilution.

QuantiFERON: Growth with Competitive and Pricing Pressure

QuantiFERON, QIAGEN’s flagship latent tuberculosis (TB) testing platform, remained a strong growth driver, posting 5% CER growth in Q4 and 10% CER for full-year 2025. Management highlighted a next-generation TB assay that boosts throughput by roughly 75% and cuts turnaround time by about 25%, with a U.S. launch planned for 2026 to tap an underpenetrated latent TB market. However, the company also acknowledged rising competition and indicated it is prepared to use pricing flexibility and longer-term contracts to defend and grow volume. While this could pressurize margins on some deals, management appears focused on protecting share and expanding the overall market.

QIAstat: Rapid Growth and Expanding Installed Base

The QIAstat syndromic testing platform delivered some of the fastest growth across the portfolio, with sales up 15% CER in Q4 and 24% CER for full-year 2025. The installed base has now surpassed 5,200 instruments, supporting a growing stream of consumables revenue. Menu expansion, including new blood culture panels, is expected to further increase utilization and drive consumable-led growth. Management is targeting about $160 million in QIAstat sales for 2026, underscoring its confidence that this platform can be a major contributor as healthcare systems continue to adopt syndromic testing.

QIAcuity: Digital PCR Consumables Outpace Instrument Demand

In digital PCR, QIAcuity continued to gain traction with consumables delivering double-digit growth in 2025. The cumulative installed base now exceeds 3,200 systems, and Q4 saw more than 100 instruments placed despite a cautious capital spending environment. That environment, particularly in research and academia, has delayed some instrument purchases and tempered the pace of hardware-driven revenue. Still, robust consumable growth shows that once systems are installed, usage ramps, supporting a more recurring, less cyclical revenue stream over time.

QIAGEN Digital Insights: Bioinformatics and AI Push

QIAGEN Digital Insights (QDI), the company’s bioinformatics arm, maintained its growth trajectory, helped by the integration of Genoox and the rollout of AI-enabled workflows. QIAGEN plans to launch roughly 14 AI-enabled software solutions over the next two years, aiming to further embed itself in genomic interpretation and clinical decision support workflows. The company is targeting around $125 million in QDI sales in 2026, with this higher-margin, software-driven business providing diversification away from pure reagent and instrument sales and reinforcing QIAGEN’s long-term digital strategy.

Margin Expansion and Profitability Despite Headwinds

Profitability improved meaningfully in 2025. Adjusted operating income margin expanded by 80 basis points to 29.5%. Importantly, management noted that tariffs and adverse FX shaved about 120 basis points off margins; excluding these factors, underlying margin expansion was closer to 200 basis points. This performance strengthens QIAGEN’s case for eventually achieving a midterm operating margin of above 31%, even as it absorbs inflation, invests in growth, and faces acquisition-related dilution.

Strong Cash Generation and Capital Returns

QIAGEN generated $654 million in operating cash flow and $453 million in free cash flow in 2025. While free cash flow lagged operating cash flow due to elevated capital expenditures—largely IT-related investments such as an SAP upgrade—and cash payments of about $54 million tied to efficiency initiatives, the company still showed ample financial flexibility. Since 2024, QIAGEN has returned more than $1.1 billion to shareholders and in January 2026 completed a $500 million synthetic share repurchase. Pro forma net leverage stands at roughly 1.3x net debt to adjusted EBITDA, leaving capacity for further strategic investments or shareholder returns.

PCR Product Group Under Pressure

Not all parts of the portfolio are growing. QIAGEN’s PCR product group saw a 9% CER sales decline in Q4 2025. While QIAcuity digital PCR consumables performed well, other PCR consumables fell, hurt by a cautious funding environment and lower OEM contributions compared to 2024. This highlights a shift within the company’s molecular testing portfolio: newer platforms and higher-value applications are offsetting weakness in more traditional PCR lines, but the drag in these legacy areas remains a headwind for near-term growth.

NGS Consumables and Genomics Headwinds

The Genomics/NGS product group also faced pressure through 2025, with NGS consumables showing weakness despite the double-digit growth posted by QDI. This suggests that customers are still cautious on consumable spending for next-generation sequencing workflows, even as demand for related software and analytics grows. For investors, the contrast underscores one of QIAGEN’s strategic rationales: building out higher-margin digital and informatics offerings to complement more cyclical hardware and consumables businesses.

Regional Softness in Americas and China

Geographically, growth was uneven. In the Americas, Q4 sales declined 1% at CER, with the U.S. flat, partly due to the temporary impact of the U.S. government shutdown on ordering patterns. China was weaker, with Q4 sales down in the low-teens at CER. Although China currently represents only about 4% of total sales, management expects this market to remain low single-digit to flat or even negative in the near term. The softness in these regions is an added layer of macro risk, even if the overall portfolio remains geographically diversified.

Tariffs, Currency and Acquisition Drag on 2026 Margins

Tariffs and foreign exchange were a notable drag in 2025, shaving about 120 basis points off operating margin. Management expects combined headwinds of around 160 basis points in 2026 from tariffs, FX and dilution from the Parse acquisition. The Parse deal alone is expected to dilute margin by roughly 100 basis points in 2026 and reduce Q1 2026 EPS by about $0.02. While these effects are near-term negatives, management is positioning Parse as a strategic asset that expands QIAGEN’s reach into the fast-growing single-cell market, with the potential to be accretive longer term.

First-Quarter and Near-Term Headwinds

The company was explicit about several temporary pressures weighing on Q1 2026 performance. Discontinuation of the NeuMoDx and Dialunox product lines will reduce sales by about $10 million, or roughly 2 percentage points of growth. A similarly sized impact—around $10 million—is expected from cautious life science customer spending, and a tough comparison in QuantiFERON from a strong Q1 2025 is expected to be a $6–7 million headwind. On top of this, Parse will dilute Q1 EPS by about $0.02 and U.S. tariffs by roughly another $0.02. While these factors constrain near-term results, management framed them as transitional rather than structural.

Sluggish Capital Spending and Investment Impact on Cash Flow

Slower capital spending, particularly in research and academic markets, weighed on instrument placements for platforms such as digital PCR. This has pushed some expected revenue into future periods, even as consumables usage continues to rise. Additionally, free cash flow of $453 million fell below operating cash flow because of higher capex—mainly for IT upgrades—and cash outlays for efficiency programs. These investments dampen near-term cash flexibility but are intended to support future scalability and cost savings.

Forward-Looking Guidance and Growth Outlook

For 2026, QIAGEN guided to at least 5% net sales growth at CER and adjusted diluted EPS of at least $2.50 at CER, with the adjusted operating margin expected to hold around 29.5% despite roughly 160 basis points of headwinds from Parse, tariffs and FX. Currency is expected to contribute about 1 percentage point to full-year sales growth (neutral to EPS) and provide a 2–3 point tailwind to Q1 sales. For the first quarter, management anticipates at least 1% CER sales growth versus $483 million in Q1 2025 and adjusted EPS of at least $0.54 at CER, slightly below last year’s $0.55 given the headwinds discussed. The first half of 2026 is expected to grow about 2–3% at CER, with acceleration in the second half needed to achieve the full-year target and a normalized run-rate closer to 6% CER once temporary effects roll off. Growth pillars are expected to expand around 9% at CER in 2026, with Sample Technologies targeted at roughly $720 million, QuantiFERON at about $535 million, QIAstat at $160 million, QIAcuity at $100 million, and QDI at $125 million. The company also highlighted completion of a $500 million share repurchase in January and maintained pro forma leverage of around 1.3x net debt to adjusted EBITDA, signaling continued balance sheet strength.

In sum, QIAGEN’s latest earnings call painted a picture of a company executing well on its strategy while navigating industry and macro headwinds. Core growth platforms are scaling, margins are expanding on an underlying basis, and cash generation remains robust, enabling both investment and shareholder returns. Yet, investors should also weigh the near-term pressures from declining legacy PCR and NGS consumables, regional softness, tariffs, and acquisition-related dilution. Management’s message was that 2026 will be a year of transition—with a slower start and stronger finish—as its growth pillars and recent acquisitions increasingly drive the story.